---
title: "Eupraxia Pharmaceuticals (EPRX) Receives a Buy from Cantor Fitzgerald"
description: "Eupraxia Pharmaceuticals (EPRX) has received a Buy rating from Cantor Fitzgerald, with a price target of $19.00 set by analyst Kristen Kluska. Kluska, a 5-star analyst, has an average return of 24.4% "
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/277489520.md"
published_at: "2026-03-02T15:16:01.000Z"
---

# Eupraxia Pharmaceuticals (EPRX) Receives a Buy from Cantor Fitzgerald

> Eupraxia Pharmaceuticals (EPRX) has received a Buy rating from Cantor Fitzgerald, with a price target of $19.00 set by analyst Kristen Kluska. Kluska, a 5-star analyst, has an average return of 24.4% and a success rate of 46.75%. The consensus for Eupraxia Pharmaceuticals is a Strong Buy, with a price target consensus of $15.22.

In a report released yesterday, Kristen Kluska from Cantor Fitzgerald maintained a Buy rating on Eupraxia Pharmaceuticals, with a price target of $19.00.

### Claim 50% Off TipRanks Premium

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential

According to TipRanks, Kluska is a 5-star analyst with an average return of 24.4% and a 46.75% success rate. Kluska covers the Healthcare sector, focusing on stocks such as Disc Medicine, DBV Technologies SA – American, and Soleno Therapeutics.

Eupraxia Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $15.22.

### Related Stocks

- [PBE.US - Invesco Biotechnology & Genome ETF](https://longbridge.com/en/quote/PBE.US.md)
- [FBT.US - First Trust NYSE Arca Biotech Index Fd](https://longbridge.com/en/quote/FBT.US.md)
- [BIB.US - Proshares Ultra Nasdaq Biotech](https://longbridge.com/en/quote/BIB.US.md)
- [ARKG.US - Ark Genomic Revolution ETF](https://longbridge.com/en/quote/ARKG.US.md)
- [VRTX.US - Vertex Pharma](https://longbridge.com/en/quote/VRTX.US.md)
- [SBIO.US - ALPS Medical Breakthrough](https://longbridge.com/en/quote/SBIO.US.md)
- [EPRX.US - Eupraxia Pharmaceuticals](https://longbridge.com/en/quote/EPRX.US.md)
- [NEUP.US - Neuphoria Therapeutics](https://longbridge.com/en/quote/NEUP.US.md)
- [XLV.US - Health Care Select Sector SPDR](https://longbridge.com/en/quote/XLV.US.md)
- [IBB.US - iShares Biotechnology ETF](https://longbridge.com/en/quote/IBB.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Craig-Hallum 维持对 Apogee Therapeutics (APGE) 的买入评级 | Craig-Hallum 分析师 Adam Vogel 对 Apogee Therapeutics (APGE) 维持了买入评级，目标价为 116.00 美元。Vogel 是一位三星分析师，平均回报率为 19.1%，成功率为 62.50%， | [Link](https://longbridge.com/en/news/277492684.md) |
| Milestone Pharmaceuticals Inc. (NASDAQ:MIST) 的空头头寸更新 | Milestone Pharmaceuticals Inc.（纳斯达克代码：MIST）在二月份的空头头寸下降了 22.1%，总计为 7,474,168 股。约有 10.9% 的股票被做空，空头头寸比率为 3.6 天。内部交易显示出显著的销售 | [Link](https://longbridge.com/en/news/277445537.md) |
| CDC 代理主任 Bhattacharya 支持使用麻疹疫苗 | 3 月 2 日（路透社）- 美国疾病控制与预防中心代理主任 Jay Bhattacharya 周一表示，该机构继续增加资源，以支持控制国内麻疹传播的预防和应对工作。他还在社交媒体平台 X 上发布的视频中表示，MMR 疫苗仍然是预防麻疹最可靠 | [Link](https://longbridge.com/en/news/277507258.md) |
| Dyne Therapeutics 第四季度净亏损收窄，超出分析师的预期 | Dyne Therapeutics 报告第四季度净亏损有所收窄，超出分析师预期。该公司保持到 2028 年第一季度的现金流，并计划在 2026 年第二季度提交美国加速批准 z-rostudirsen 的申请，预计在 2027 年第一季度推出 | [Link](https://longbridge.com/en/news/277464907.md) |
| Xeris Biopharma 第四季度的产品收入超出了分析师的预期，主要是由于患者需求的增加 | Xeris Biopharma 报告第四季度创纪录的收入为 8343 万美元，超出分析师预期，净收入为 1110 万美元，而去年则出现亏损。该公司预计 2026 年收入将在 3.75 亿至 3.9 亿美元之间，同时研发和销售及管理费用将增加 | [Link](https://longbridge.com/en/news/277460502.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.